Loading clinical trials...
Loading clinical trials...
A 9 Month, Double-Blind, Placebo-Controlled Study With a Blinded Crossover Transition to Open-Label Extension, Evaluating the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Type 2 Diabetes Patients
Conditions
Interventions
topiramate
Start Date
April 1, 2000
Completion Date
May 1, 2002
Last Updated
June 8, 2011
NCT07472881
NCT01143454
NCT07010757
NCT06989203
NCT06223555
NCT07237750
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions